EUCTR2006-004565-33-DE进行中（未招募）不适用
Efficacy and safety of Aethoxysklerol compared to Sodium Tetradecyl Sulfate and Isotonic Saline (placebo) for the treatment of reticular veins and spider veins including subgroup to investigate the plasma concentrations of polidocanol
Chemische Fabrik Kreussler & Co.GmbH0 个研究点开始时间: 2007年1月19日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Male / female
- •2.Age between 18 and 70 years
- •3.C1 veins (see definition in Section 3.2)
- •4. Willing and able to provide written informed consent to a participation in the study after having been informed by the investigator about the aim, course and possible risks of the study
- •5.For females of childbearing potential: must be willing and able to use reliable contraceptive methods throughout the study. Reliable methods for women are hormonal contraceptives, surgical intervention (e.g. tubal ligation), intrauterine device (IUD) and sexual abstinence.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Patients with C2-C6 venous insufficiency (which could influence the treatment success of C1 veins in this study)
- •2.Patients with CEAP-classifications: Es und Ec, AD, PO
- •3.Patients who have already undergone sclerotherapy, laser treatment and surgery during the last twelve weeks of the ipsilateral leg or during the last four weeks of the contralateral leg
- •4.Acute superficial or deep vein thrombosis
- •5.History of major superficial thrombosis
- •6.Patients with positive result for one of the following thrombophilia indicators: Activated Protein C resistance, increased Factor VIII activity, Antithrombin III deficiency, Protein C deficiency, Protein S deficiency, Prothrombin 20210 gene mutation, and Antiphospholipid syndrome as determined by analyzing blood samples taken on day 0
- •7.History or evidence of previous deep vein thrombosis
- •8.Patients with all of the following risk factors of thrombosis:
- •- taking hormonal contraceptives or receiving hormone replacement therapy and
- •- adiposity (body mass index greater than 30) and
- •9.Patients with other factors implicating a risk of thrombosis (e.g. recent long-distance flight) as judged by investigator
- •10.Known coagulopathy
- •11.Patients with known hereditary thrombophilia
- •12.Major leg edema (if it cannot be influenced by compression therapy)
- •13.Inflammatory skin disease in the area of treatment
- •14.Arterial occlusive disease (Fontaine Stage II or more)
- •15.Clinically relevant abnormalities in the 12-lead electrocardiogram (ECG).
- •16.Known hypersensitivity to polidocanol (macrogol lauryl ether, lauromacrogol 400) or any of the other ingredients of Aethoxysklerolâ
- •17.Known hypersensitivity to Sodium Tetradecyl Sulfate or any of the other ingredients of Sotradecol®
- •18.Known pronounced allergic disposition
- •19.Acute severe systemic disease or poor general health
- •20.Severe generalized infection
- •21.Acute febrile states
- •22.Reduced mobility
- •23.Bronchial asthma or known strong predisposition to allergies
- •24.Symptoms of microangiopathy or neuropathy
- •25.Pregnant women
- •26.Lactating women
- •27.Antipathy against the treatment procedures, aftercare and the follow-up
- •28.Any participation in another clinical study within 4 weeks (30 days) prior to enrolment in this study.
- •29.Known history of HIV
- •30.Known history of hepatitis B or C.
- •31.History or acute state of alcoholism (5% ethanol content in the study medication) or substance abuse.
- •32.Regular use of disulfiram (e.g. antibuse) or similar medication.
- •33.Regular use of anticoagulants (except platelet aggregation inhibitors, i.e. low dose ASS)
研究者
相似试验
进行中（未招募）
不适用
Efficacy and safety of Aethoxysklerol 4% compared to 5% phenol in oil for the treatment of the first and second degree hemorrhoids - a pilot studyFirst and second degree hemorrhoidsMedDRA version: 9.1Level: LLTClassification code 10016701Term: First degree haemorrhoidsMedDRA version: 9.1Level: LLTClassification code 10039799Term: Second degree haemorrhoidsMedDRA version: 9.1Level: LLTClassification code 10060718Term: Hemorrhoidal sclerotherapyEUCTR2007-001471-11-DEChemische Fabrik Kreussler & Co. GmbH
已完成
不适用
Evaluation of efficacy and safety of anti-sclerostin antibody romosozumab for osteoporosis in patients undergoing hemodialysisosteoporosis, end stage renal diseaseJPRN-UMIN000037579Tokai University School of Medicine25
进行中（未招募）
不适用
The Comparison of the Efficacy and Safety of Arzoxifene versus Raloxifene in Postmenopausal Women with Osteoporosis. - NDPrevention and treatment of osteoporosis.MedDRA version: 6.1Level: PTClassification code 10031285EUCTR2006-001987-22-ITEli Lilly and Company Limited300
尚未招募
4 期
Abexol and Atorvastatin in the non alcoholic steatohepatitison-Alcoholic Steatohepatitis (NASH)Non-alcoholic Fatty Liver DiseaseLiver DiseasesDigestive System DiseasesFatty LiverRPCEC00000221Center of Natural Products, National Center for Scientific Research100
进行中（未招募）
1 期
Evaluation of thesafety and efficacy of ambroxol in Gaucher disease caused by carrying the c.1448T>C mutation (p.Leu483Pro) and other rare variants of the GBA gene, based on clinical evaluation and results of genetic and metabolomic analysesGaucher diseaseEUCTR2021-006224-40-PLInstytut ,,Pomnik-Centrum Zdrowia Dziecka40